These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9258810)

  • 1. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
    Guido R; Valenti S; Foppiani L; De Martini D; Cossu M; Giusti M
    J Endocrinol Invest; 1997 May; 20(5):289-93. PubMed ID: 9258810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
    Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V; Freneau E; Morange I; Simonetta C
    Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW; Atkin SL; Savage MW; Masson EA; White MC
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
    Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E; Crabbé J; Donckier J
    Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinagolide in the management of prolactinoma.
    Schultz PN; Ginsberg L; McCutcheon IE; Samaan N; Leavens M; Gagel RF
    Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
    Serri O; Beauregard H; Lesage J; Pedneault L; Comtois R; Jilwan N; Somma M; Vachon L; Brownell J
    J Clin Endocrinol Metab; 1990 Sep; 71(3):682-7. PubMed ID: 2394774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ; Brownell J; Lamberts SW
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.